- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Call
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Jim Whittle
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Nadia Kershaw
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Sarah Best
- Dr Saskia Freytag
- Dr Shabih Shakeel
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Mark Eaton
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marco Herold
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sant-Rayn Pasricha
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A new regulator of 'stemness' to create dendritic cell factories for immunotherapy
- Advanced imaging interrogation of pathogen induced NETosis
- Cancer driver deserts
- Cryo-electron microscopy of Wnt signalling complexes
- Deciphering the heterogeneity of breast cancer at the epigenetic and genetic levels
- Developing drugs to block malaria transmission
- Developing new computational tools for CRISPR genomics to advance cancer research
- Developing novel antibody-based methods for regulating apoptotic cell death
- Discovering novel paradigms to cure viral and bacterial infections
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Do membrane forces govern assembly of the deadly apoptotic pore?
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- E3 ubiquitin ligases in neurodegeneration, autoinflammation and cancer
- Engineering improved CAR-T cell therapies
- Epigenetic biomarkers of tuberculosis infection
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- Genomic rearrangement detection with third generation sequencing technology
- How does DNA damage shape disease susceptibility over a lifetime?
- How does DNA hypermutation shape the development of solid tumours?
- How platelets prevent neonatal stroke
- Human lung protective immunity to tuberculosis
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of dysregulated Tom40 in neurodegeneration
- Investigating the role of mutant p53 in cancer
- Lupus: proteasome inhibitors and inflammation
- Machine learning methods for somatic genome rearrangement detection
- Malaria: going bananas for sex
- Measurements of malaria parasite and erythrocyte membrane interactions using cutting-edge microscopy
- Measuring susceptibility of cancer cells to BH3-mimetics
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Mutational signatures of structural variation
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Revealing the epigenetic origins of immune disease
- Reversing antimalarial resistance in human malaria parasites
- Structural and functional analysis of DNA repair complexes
- Targeting human infective coronaviruses using alpaca antibodies
- Towards targeting altered glial biology in high-grade brain cancers
- Uncovering the real impact of persistent malaria infections
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding how malaria parasites sabotage acquisition of immunity
- Understanding malaria infection dynamics
- Understanding the mechanism of type I cytokine receptor activation
- Unveiling the heterogeneity of small cell lung cancer
- Using alpaca antibodies to understand malaria invasion and transmission
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to cross the blood brain barrier for drug delivery
- Using structural biology to understand programmed cell death
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
New blood test could spare thousands of colon cancer patients from unnecessary chemotherapy
8 June 2022
Researchers have developed a new blood test that could revolutionise how chemotherapy is used for colon cancer, by identifying the patients that need chemo and those that can be safely spared treatment.
More than 450 patients and over 20 hospitals from across Australia were involved in the world first clinical trial, which investigated the blood test as a promising aid to cancer treatment decision-making.
The study, co-led by WEHI and the Johns Hopkins Kimmel Cancer Centre in the US, found the test could accurately predict which patients would benefit from chemotherapy after their cancer is surgically removed.
At a glance
- Australian-American researchers have co-designed a blood test that uses circulating tumour DNA (ctDNA) to precisely identify the stage II colon cancer patients that need chemotherapy after surgery.
- It is the first clinical study to determine whether patients should receive chemotherapy based on their ctDNA result. There was no method of identifying which stage II colon cancer patients would benefit from chemo before this test.
- The blood test has the potential to revolutionise how chemotherapy is used for colon cancer patients and accelerate the development of promising new treatment options.
Stage II colon cancer is defined as a cancer that has grown through the wall of the colon, but does not extend to the lymph nodes or other organs. Nearly 4,000 Australians are diagnosed with it each year.
While most patients with stage II colon cancer are cured after surgery to remove the cancer from the bowel, the cancer will recur in around 20 per cent of patients.
Chemotherapy is currently offered to all stage II colon cancer patients despite a majority not needing it.
WEHI’s Associate Professor Jeanne Tie and Professor Peter Gibbs collaborated with the Johns Hopkins Kimmel Cancer Centre to develop a novel blood test to identify patients who require chemo after surgery.
The test assesses levels of circulating tumour DNA (ctDNA) – genetic material shed from tumours into the bloodstream.
The findings from this landmark study, published in The New England Journal of Medicine, could revolutionise chemotherapy treatment for colon cancer patients and fast-track the development of new drug targets.
DYNAMIC results
The goal of chemotherapy when given after colon cancer surgery is to eradicate micrometastases – cancer cells that have travelled from the original cancer in the bowel through the bloodstream to deposit in another site, such as the liver.
These deposits of cancer cells are miniscule and are not seen at surgery or on radiologic images during the initial stages. However, they will gradually increase in size and become large enough to be seen on a standard CT scan if they are not treated with chemotherapy.
The novel blood test, co-developed by WEHI, can detect these invisible cells that release tiny amounts of ctDNA into the bloodstream, enabling researchers to identify which patients should be offered chemotherapy based on whether micrometastases has been detected.
Associate Professor Jeanne Tie - a clinician scientist at WEHI and a medical oncologist at the Peter MacCallum Cancer Centre - said the DYNAMIC study solved a significant health barrier that has been intensely researched for decades: how experts can decide which patients should be recommended for chemotherapy and which patients can safely avoid the treatment.
“Our trial has conclusively shown how the ctDNA blood test can be used to direct post-surgical therapy in stage II colon cancer and substantially reduce the number of patients treated with chemotherapy, without impacting the risk of cancer relapse,” Associate Professor Tie said.
“We found that when a patient’s blood test does not reveal ctDNA after colon surgery, the likelihood of micrometastases is very low and chemotherapy can be avoided as there are no tumour fragments left to kill.”
The findings are globally significant as previously there was no way of determining whether all the cancer had been removed through colon surgery.
“While chemotherapy can be essential and lifesaving, many patients are receiving the treatment and its associated toxicities without any benefit,” Associate Professor Tie said.
“This ctDNA blood test could be used to spare around 600 Australians and over 100,000 people worldwide from unnecessary chemo treatments each year.”
Collaborative power
While previous studies have suggested ctDNA measurements could be used to determine the risk of cancer recurrence, the DYNAMIC study is the first randomised study in the world to provide the clinical evidence required to move this from a promising blood test to one that should be routinely used in clinical practice.
Associate Professor Jeanne Tie
Co-lead author Professor Peter Gibbs said the study would not have been possible without the 23 Australian hospitals that enrolled 455 patients for the multi-centre trial since 2015.
“The collaborative efforts from these hospitals were critical for us to complete this trial, the first randomised trial in any solid tumor type worldwide that used a blood test to determine which patients can safely forgo chemotherapy after surgery,” Associate Professor Gibbs said.
“Randomised studies like this are needed to deliver meaningful patient outcomes, but they are not possible without the support of our collaborators and philanthropic efforts.”
Victoria’s Western Health hospital contributed the largest number of patients for the trial, while Peter McCallum Cancer Centre was the lead clinical site.
Other hospitals involved were: Barwon Health, Bendigo Health, Border Medical, Cabrini Hospital, Eastern Health, Epworth Freemasons, Flinders Medical Centre, Melbourne Private Hospital, Monash Health, Nepean Cancer Centre, Northern Hospital, Peter MacCallum Cancer Centre, South West Health Care, St Vincent’s Hospital Melbourne, Western Private Hospital (VIC); Border Medical Oncology, Calvary Mater Newcastle Hospital, Chris O’Brien Lifehouse, Newcastle Private Hospital (NSW); Canberra Hospital (ACT), Fiona Stanley Hospital (WA), Royal Hobart Hospital (TAS) and the Royal Brisbane and Women’s Hospital (QLD).
Researchers hope to demonstrate the value of ctDNA-informed treatment in other stages of colon cancer and other cancer types, including pancreas and ovarian cancer, with three additional randomised studies already underway.
“Our ctDNA test can be used to reduce the physical and financial toxicity brought on by unnecessary chemo treatments and believe our findings bring us closer to significantly improving treatment options for many patients across a broad range of cancer types,” Professor Gibbs said.
The research was supported by: NHMRC, Medical Research Future Fund, Marcus Foundation, Virginia and D.K. Ludwig Fund for Cancer Research, Lustgarten Foundation, Conrad R. Hilton Foundation, Sol Goldman Charitable Trust, John Templeton Foundation, National Institutes of Health and Eastern Health Research Foundation.
WEHI authors
Jeanne Tie, Rachel Wong, Margaret Lee, Belinda Lee and Peter Gibbs
Media enquiries
M: +61 475 751 811
Super Content:
A biomarker in the blood of patients with bowel cancer may provide valuable insight into the risk of cancer relapse after surgery and the effectiveness of chemotherapy.
Clinician scientists Associate Professor Jeanne Tie and Associate Professor Sumitra Ananda are leading trials of a blood test to guide cancer treatment after surgery.
Want to be informed of our most exciting discoveries? Subscribe to our quarterly newsletter, Illuminate.